What is the purpose of the RegenesomeTech Forum 2026?

The purpose is to report on the progress of business and research to date, and to outline the longevity research strategy for this year, focusing on 'brain' and 'nanoparticles'.

Why are nanoparticles important in longevity research?

The brain has a defense mechanism called the blood-brain barrier (BBB) that blocks drug delivery. Using precisely designed nanoparticles can protect active ingredients from degradation and ensure their delivery to the target tissue, the brain.

What is the technical direction of this year's research strategy?

We will focus on the brain as the target area and use nanoparticles as the core technology. Additionally, we aim to further streamline research and development using AI.

Who were the guests at the forum?

Three guests appeared: Taizo Ichihara from Japan System Technology Co., Ltd. (medical big data), Takahiro Yasuda, Associate Professor at Tokyo University of Science (pre-disease control), and Shinnoji Mizuno from FastNeura Inc. (neurotechnology and AI).

What are the roles of Space Seed Holdings and Regenesome?

Space Seed Holdings oversees deep technology-related businesses, while its subsidiary Regenesome is responsible for research and development in the longevity field and the social implementation of food-derived nanoparticles, among others.

Regenesome Tech Forum 2026 Held: Reporting Business Progress and Longevity Research Strategy

Published May 26, 2026 6:40 AM ・ Updated Jun 14, 2026 8:05 AM ・ 9 min read ・ Source: PR TIMES

Space Seed Holdings and Regenesome hosted the 'Regenesome Tech Forum 2026' on April 23, 2026. The event featured updates on business progress and the unveiling of a new research strategy focused on brain-targeted nanoparticle studies and AI-driven R&D efficiency.

Regenesome Tech Forum 2026 Held: Reporting Business Progress and Longevity Research Strategy

Space Seed Holdings Inc. (HQ: Minato-ku, Tokyo; CEO: Kengo Suzuki) and its subsidiary dedicated to the medical sector, Regenesome Inc. (HQ: Minato-ku, Tokyo; President: Zentaro Sakuma), hosted the 'Regenesome Tech Forum 2026' on April 23, 2026. At the forum, the companies reported on their business progress and research achievements, while outlining their research strategy for this fiscal year, which focuses on brain-targeted research within the longevity field, using 'nanoparticles' as a core technological approach.

In the first half of the session, Zentaro Sakuma, President of Regenesome, reported on the business development and financial status of the food brand 'Gindou.' In the second half, Kengo Suzuki, CEO of Space Seed Holdings and CEO of Regenesome, shared his vision for streamlining research and development by utilizing AI, building upon the research accomplishments accumulated thus far. Additionally, external guests were invited to engage in discussions on the forefront of neurotechnology and brain science.

### The Relationship Between the Brain and Nanoparticles

The brain is equipped with a robust defense mechanism called the 'blood-brain barrier (BBB)' that prevents the entry of harmful substances. This barrier is the greatest obstacle to the delivery of many drugs and functional ingredients to the brain. Nanoparticles can carry active ingredients to target tissues while protecting them from decomposition through precise control of particle size and surface design. Research into this approach is advancing globally as a potent method for crossing the BBB and controlling distribution within the brain. In brain-focused longevity research, how to deliver ingredients to the brain is considered just as critically important as finding effective ingredients, and nanoparticle design is believed to hold the key.

### Guest Speakers

Three guests who support Regenesome's research and business activities participated in the forum:

- **Taisuke Ichihara**, Future Co-creation Lab, Healthcare Innovation Division, Japan System Techniques Co., Ltd. (JAST) As an independent IT company listed on the Prime Market of the Tokyo Stock Exchange, JAST specializes in medical big data. A partner that has long supported Regenesome, the company shared its vision for advancing the business by leveraging its medical data covering approximately 10 million people and its years of systems development expertise.

- **Takahiro Adachi**, Associate Professor, Institute of Medical Science, Tokyo University of Science (TUS), Department of Mibyo Control Specializing in B-cell signaling, intestinal immunity, and bio-imaging, Professor Adachi provided insights into longevity research based on his knowledge connecting food, immunity, and 'Mibyo' (the state of being between health and illness).

- **Shinnosuke Mizuno**, CNTO, FastNeura Inc. Leading the overall management and joint research for 'Sync,' a cognitive expansion system from a company that integrates neurotechnology and AI. Currently a student at the University of Tokyo Faculty of Medicine, Mizuno discussed the technologies for approaching the brain and the possibilities of AI application from the dual perspective of neurophysiological research (presented at domestic conferences) and AI/LLM research.

### Forum Overview

- **Name:** Regenesome Tech Forum 2026 - **Date/Time:** April 23, 2026 (Thu), 17:00–19:00 - **Venue:** TAKANAWA GATEWAY Link Scholars' Hub (LiSH) Studio1/Lab - **Organizers:** Regenesome Inc. / Space Seed Holdings Inc.

### Company Profiles

**Regenesome Inc.** - Business: R&D in the longevity sector. Research and social implementation of drug delivery technologies, including food-derived nanoparticles. - Representative: Zentaro Sakuma - Website: https://regenesome.com/

**Space Seed Holdings Inc.** - Founded: January 2024 - Business: Space utilization research and other deep tech-related businesses. - Representative: Kengo Suzuki - Website: https://ss-hd.co.jp/

FACT BOX

Source: PR TIMES
Category: Event

Regenesome Tech Forum 2026 Held: Reporting Business Progress and Longevity Research Strategy

⚡ Key Points

Regenesome Tech Forum 2026 Held: Reporting Business Progress and Longevity Research Strategy

FACT BOX

Editorial & Verification Standards

FAQ

Cite this article — HOW TO CITE

AI CRAWLER ACTIVITY